ClearPoint Neuro (NASDAQ:CLPT) Director Lynnette Fallon Sells 5,091 Shares

Posted by Brenda Bartman on May 22nd, 2026

ClearPoint Neuro, Inc. (NASDAQ:CLPT – Get Free Report) Director Lynnette Fallon sold 5,091 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $11.14, for a total value of $56,713.74. Following the completion of the sale, the director directly owned 48,227 shares of the company’s stock, valued at $537,248.78. The trade was a 9.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

ClearPoint Neuro Stock Performance

Shares of CLPT opened at $11.70 on Friday. The company’s 50 day simple moving average is $10.56 and its 200-day simple moving average is $12.80. The firm has a market cap of $350.88 million, a PE ratio of -11.58 and a beta of 1.29. ClearPoint Neuro, Inc. has a 12-month low of $8.27 and a 12-month high of $30.10. The company has a current ratio of 5.79, a quick ratio of 4.88 and a debt-to-equity ratio of 2.63.

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.The business had revenue of $12.13 million for the quarter, compared to analyst estimates of $11.97 million. As a group, equities analysts predict that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on CLPT. Stifel Nicolaus assumed coverage on ClearPoint Neuro in a research note on Friday, May 8th. They set a “buy” rating and a $16.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. Finally, B. Riley Financial boosted their target price on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Read Our Latest Research Report on CLPT

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC raised its holdings in ClearPoint Neuro by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 65,557 shares of the company’s stock worth $897,000 after purchasing an additional 1,109 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in ClearPoint Neuro by 4.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,791 shares of the company’s stock worth $367,000 after purchasing an additional 1,204 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in ClearPoint Neuro during the 4th quarter worth approximately $25,000. Huntington National Bank purchased a new position in shares of ClearPoint Neuro during the 3rd quarter worth approximately $44,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of ClearPoint Neuro by 2,435.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after buying an additional 2,143 shares during the period. 30.08% of the stock is currently owned by institutional investors and hedge funds.

About ClearPoint Neuro

(Get Free Report)

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.